Generic Revlimid patent expiry impact
Patent expiry in January 2026 could lead to pricing erosion and market share loss; management acknowledged uncertainty but plans to continue supply post-expiry.
high · analyst_question
Aurobindo Pharma Limited — Q3 FY25
Aurobindo Pharma delivered its highest-ever quarterly revenue of INR 7,979 crore in Q3 FY25, driven by robust US base product sales, strong European growth (+23% YoY), and expan...
bullish
high
✓ Verified against BSE filing
Risk Intelligence
Material risks this quarter
Concise cards keep the risk register scannable while preserving evidence-level context in the underlying quarter data.
Risks
Eugia injectables capacity ramp-up delays
Capacity utilization at Eugia remains at 50% due to supply challenges; any further delays in returning to normal run-rate could impact US injectable revenue.
medium · management_commentaryBiosimilar clinical trial delays
Omalizumab and ophthalmic product trials are delayed; ophthalmic recruitment only 50% and expected to complete in H2 2026, pushing back potential launches.
medium · management_commentaryUS tariff risk on pharmaceuticals
Potential US tariffs on pharmaceutical imports could impact margins; management believes existing US manufacturing footprint provides mitigation.
medium · analyst_question